Picard Medical Unveils Next-Gen Artificial Heart Architecture at IEEE EMBC — Picard Medical, Inc.

Event summary

Picard Medical presented the Emperor Total Artificial Heart architecture for the first time at IEEE EMBC 2026 on July 26-30.
The presentation detailed the integration of the patent-pending Emperor Drive System with SynCardia’s clinically proven ventricles.
The Emperor TAH aims to advance toward full implantability, replacing current pneumatic drivers with a compact electromechanical system.
Preclinical evaluations showed physiologic preload-dependent output and stable performance in mock circulation testing.

The big picture

Picard Medical’s Emperor TAH represents a strategic pivot toward fully implantable artificial hearts, leveraging SynCardia’s established clinical foundation. The shift from pneumatic to electromechanical drivers aligns with broader industry trends toward miniaturization and patient mobility in cardiac care. With over 2,100 implants of the SynCardia device globally, Picard Medical is positioning itself as a leader in next-generation heart failure solutions.

What we're watching

Regulatory Pathway: Whether the Emperor TAH can secure FDA approval faster than competitors, given its reliance on proven SynCardia components.
Technical Execution: The pace at which Picard Medical advances from preclinical testing to human trials for the Emperor Drive System.
Market Adoption: How transplant centers will integrate the next-gen artificial heart into existing workflows, given its potential mobility and quality-of-life benefits.